Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome Of Elderly Patients With Acute Myeloid Leukemia In First Complete Remission: A Time-Dependent And Multistate Analysis From The French Innovative Leukemia Organization

Allogeneic stem cell transplantation (AlloSCT) is a curative option for acute myeloid leukemia (AML) patients. In first complete remission (CR1), young patients (< 60 years) with intermediate or unfavorable ELN disease risk are usually considered for AlloSCT. In contrast, because of the expected higher toxicity in older patients, the benefit of this treatment remains a matter of debate after 60 years, especially in the intermediate ELN risk group. In this multicenter analysis from the French Innovative Leukemia Organization (FILO), we investigated whether AlloSCT was beneficial for AML patients over 60 years old in CR1.